Biosensors to monitor MS activity.
Jennifer S GravesXavier MontalbanPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)
Advances in wearable and wireless biosensing technology pave the way for a brave new world of novel multiple sclerosis (MS) outcome measures. Our current tools for examining patients date back to the 19th century and while invaluable to the neurologist invite accompaniment from these new technologies and artificial intelligence (AI) analytical methods. While the most common biosensor tool used in MS publications to date is the accelerometer, the landscape is changing quickly with multi-sensor applications, electrodermal sensors, and wireless radiofrequency waves. Some caution is warranted to ensure novel outcomes have clear clinical relevance and stand-up to the rigors of reliability, reproducibility, and precision, but the ultimate implementation of biosensing in the MS clinical setting is inevitable.
Keyphrases
- multiple sclerosis
- artificial intelligence
- mass spectrometry
- ms ms
- machine learning
- big data
- label free
- deep learning
- end stage renal disease
- newly diagnosed
- white matter
- ejection fraction
- low cost
- liquid chromatography
- primary care
- chronic kidney disease
- gold nanoparticles
- healthcare
- prognostic factors
- sensitive detection
- type diabetes
- metabolic syndrome
- atrial fibrillation
- heart rate
- skeletal muscle
- insulin resistance
- ultrasound guided